Dual cytokine fusion proteins comprising IL-10

Inventors

Mumm, John

Assignees

Deka Biosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12145007-B2

Patent

Publication Date

2024-11-19

Expiration Date


Abstract

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

Core Innovation

The invention relates to a dual cytokine fusion protein in which IL-10, including IL-10 variants, is fused at both terminals to an antibody-derived scFv VH/VL scaffolding. In the disclosed structural embodiments, the fusion has the form IL-10—X1—(Z)n—X2—IL-10, where X1 and X2 correspond to VL/VH and VH/VL regions derived from an anti-Ebola antibody, and Z is a cytokine other than IL-10 positioned in a hinge/linker region between VH and VL.

The scFv targeting portion is constructed from VL and VH regions in which three light chain CDRs and three heavy chain CDRs are engrafted with three light chain CDRs and three heavy chain CDRs from a second monoclonal antibody. Structural formulas are provided for IL-10—X1—(Z)n—X2—IL-10, including IL-10–X1–(Z)n–X2–IL-10 embodiments and linker-based embodiments.

The examples specify IL-10 as SEQ ID No: 1, with the second antibody being an anti-HER2 monoclonal antibody and Z being IL-2 for the n=1 embodiment. Pharmaceutical compositions and therapeutic indications are disclosed for the dual cytokine fusion proteins, including cancer, inflammatory/immune diseases, and sepsis.

Claims Coverage

The partial content includes one independent claim that defines a dual cytokine fusion protein architecture with an IL-10 monomer fused to antibody-derived VL/VH regions, and a second cytokine positioned between the scFv regions. The independent claim specifies an anti-Ebola antibody contribution, CDR engrafting with a second monoclonal antibody, and an example embodiment where Z is IL-2 and the second antibody is anti-HER2 (n=1).

Dual cytokine fusion protein with IL-10 monomer flanked by anti-Ebola VL/VH and a cytokine other than IL-10

A dual cytokine fusion protein of formula (I) having NH2-(IL10)—(X1)—(Z)n—(X2)-(IL10)-COOH, wherein IL-10 is a monomer, X1 is a VL or VH region from a first monoclonal antibody and X2 is a VH or VL region from the first monoclonal antibody, n is an integer of 1, and Z is a cytokine other than IL-10.

Anti-Ebola antibody scFv regions with CDR engraftment from a second monoclonal antibody

The first monoclonal antibody is an anti-Ebola antibody, and the VL and VH from the anti-Ebola antibody include 3 light chain CDRs and 3 heavy chain CDRs that are engrafted with 3 light chain CDRs and 3 heavy chain CDRs from a second monoclonal antibody.

Example embodiment specifying IL-10 sequence, anti-HER2 second antibody, and Z as IL-2

The IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-2 (with n=1).

Across the independent claim, the inventive coverage centers on an IL-10 monomer flanked by anti-Ebola-derived VL/VH regions, with a cytokine other than IL-10 inserted as Z in the (Z)n hinge/linker region, together with scFv CDR engraftment between an anti-Ebola framework and CDRs from a second monoclonal antibody. An example embodiment specifies IL-10 as SEQ ID No: 1, an anti-HER2 second antibody, and Z as IL-2 (n=1).

Stated Advantages

Increasing T-cell IFNγ potentiation potency when IL-2 is tethered to an IL-10 scFv scaffold.

Reducing IL-2 toxicity associated with free cytokines.

Suppressing LPS-induced TNFα and inhibiting IFNγ induction when coupling IL-4 variants with IL-10 scaffolds.

Providing in vivo tumor efficacy and sepsis survival results for specific dual cytokine constructs.

Documented Applications

Cancer therapy, including in vivo tumor efficacy results for specific dual cytokine constructs.

Inflammatory/immune diseases, including described cytokine pathway effects such as suppression of LPS-induced TNFα and inhibition of IFNγ induction.

Sepsis, including described sepsis survival results for specific dual cytokine constructs.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.